| Market Capitalization (Millions $) |
16 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
27 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-36 |
| Cash Flow (TTM) (Millions $) |
-24 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Passage Bio Inc. is a genetic medicines company that specializes in developing transformative therapies for rare, monogenic central nervous system (CNS) disorders. The company utilizes its proprietary gene therapy platform to develop innovative treatments that target the underlying causes of these genetic disorders. By harnessing the power of genetic medicine, Passage Bio aims to provide long-lasting and potentially curative therapies that can significantly improve the lives of patients suffering from these rare diseases. The company's pipeline includes multiple product candidates at different stages of development, with a focus on conditions such as GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Passage Bio is committed to advancing its pipeline and partnering with experts, researchers, and patient communities to accelerate the development and delivery of life-changing treatments for rare genetic disorders.
Company Address: One Commerce Square Philadelphia 19103 PA
Company Phone Number: 866-0311 Stock Exchange / Ticker: NASDAQ PASG
|
2.86%